PDCD1 and neoplasm: LAG3 is expressed on the surface of activated CD4 and CD8 T cells [57], and Nicolas et al. found that the combination of anti-LAG-3 and anti-PD-1 enhances the cytotoxic capacity of CD8 T cells and leads to the anti-tumor effect [58].